Meningioma, Familial, Susceptibility To

Table of contents:

Description
Related genes
Clinical Features
Incidence and onset information
Alternative Names
Researches and researchers
Gene Panels
Sources and references

Description

Meningiomas are, in general, slowly growing benign tumors derived from the arachnoidal cap cells of the leptomeninges, the soft coverings of the brain and spinal cord. Meningiomas are believed to be the most common primary tumors of the central nervous system in man. The vast majority of meningiomas are sporadic; familial occurrence of meningioma is rare (Zang, 2001).Familial or multiple meningiomas may also be seen in tumor predisposition syndromes. Some patients with schwannomatosis (OMIM ), caused by mutation in the SMARCB1 gene, may develop meningiomas. One patient with malignant gliomas (GLM2 ) associated with a mutation in the PTEN gene (OMIM ) developed a meningioma (Staal et al., 2002).

Genes related to Meningioma, Familial, Susceptibility To

PTEN
SUFU
PDGFB
SMARCE1
NF2
MN1

View recommended genes panels

Clinical Features

Phenotypes and symptoms related to Meningioma, Familial, Susceptibility To

Neoplasm
Meningioma
Medulloblastoma
Neoplasm of the central nervous system

Incidence and onset information

— Currently we don't have prevalence information about this disease (Not enough data available about incidence and published cases.)
— No data available about the known clinical features onset.

Researches and researchers

Currently, we don't have any information about doctors, researches or researchers related to this disease. Please contact us if you would like to appear here.

Meningioma, Familial, Susceptibility To Recommended genes panels

Panel Name, Specifity and genes Tested/covered
PTEN Comprehensive - Sequence & Deletion/Duplication Analysis. By Baylor Miraca Genetics Laboratories (United States). PTEN Specificity 100 % Genes 17 %
PTEN Deletion/Duplication Analysis. By Baylor Miraca Genetics Laboratories (United States). PTEN Specificity 100 % Genes 17 %
PTEN Deletion/Duplication Analysis (Prenatal Diagnosis). By Baylor Miraca Genetics Laboratories (United States). PTEN Specificity 100 % Genes 17 %
PTEN Sequence Analysis. By Baylor Miraca Genetics Laboratories (United States). PTEN Specificity 100 % Genes 17 %
PTEN Sequence Analysis (Familial Mutation/Variant Analysis). By Baylor Miraca Genetics Laboratories (United States). PTEN Specificity 100 % Genes 17 %
PTEN Sequence Analysis (Prenatal Diagnosis). By Baylor Miraca Genetics Laboratories (United States). PTEN Specificity 100 % Genes 17 %
Hereditary High Risk Breast Cancer Panel. By Baylor Miraca Genetics Laboratories (United States). BRCA1, BRCA2, STK11, TP53, CDH1, PALB2, PTEN Specificity 15 % Genes 17 %
Hereditary High Risk Breast Cancer Panel. By Baylor Miraca Genetics Laboratories (United States). BRCA1, BRCA2, STK11, TP53, CDH1, PALB2, PTEN Specificity 15 % Genes 17 %

You can get up to 558 more panels with our dedicated tool

Learn more

Sources and references

You can check the following sources for additional information.

OMIM MESH Rare Disease Symptoms Checker

If you liked this article maybe you will also find interesting the following in-depth articles about other rare diseases, like NEUTROPENIA, SEVERE CONGENITAL, 1, AUTOSOMAL DOMINANT; SCN1 LONG QT SYNDROME 5; LQT5